147 related articles for article (PubMed ID: 36016109)
21. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
22. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Comirnaty
Fernández-Lázaro D; Garrosa M; Sánchez-Serrano N; Garrosa E; Jiménez-Callejo E; Pardo Yanguas MD; Mielgo-Ayuso J; Seco-Calvo J
Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893819
[TBL] [Abstract][Full Text] [Related]
24. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
Naito T; Tsuchida N; Kusunoki S; Kaneko Y; Tobita M; Hori S; Ito S
Expert Rev Vaccines; 2022 Sep; 21(9):1319-1329. PubMed ID: 35763290
[TBL] [Abstract][Full Text] [Related]
25. Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine.
Temtanakitpaisan Y; Saengnipanthkul S; Sarakosol N; Maskasame S; Mongkon S; Buranrat B; Thammawat S; Patamatamkul S; Nernsai P
Vaccine X; 2022 Dec; 12():100242. PubMed ID: 36415450
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Borobia AM; Carcas AJ; Pérez-Olmeda M; Castaño L; Bertran MJ; García-Pérez J; Campins M; Portolés A; González-Pérez M; García Morales MT; Arana-Arri E; Aldea M; Díez-Fuertes F; Fuentes I; Ascaso A; Lora D; Imaz-Ayo N; Barón-Mira LE; Agustí A; Pérez-Ingidua C; Gómez de la Cámara A; Arribas JR; Ochando J; Alcamí J; Belda-Iniesta C; Frías J;
Lancet; 2021 Jul; 398(10295):121-130. PubMed ID: 34181880
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination.
Lim SY; Kim JY; Park S; Kwon JS; Park JY; Cha HH; Suh MH; Lee HJ; Lim JS; Bae S; Jung J; Lee N; Kim K; Shum D; Jee Y; Kim SH
Immune Netw; 2021 Dec; 21(6):e41. PubMed ID: 35036028
[TBL] [Abstract][Full Text] [Related]
28. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty
Held J; Esse J; Tascilar K; Steininger P; Schober K; Irrgang P; Alsalameh R; Tenbusch M; Seggewies C; Bogdan C
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696171
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y
Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457
[TBL] [Abstract][Full Text] [Related]
30. Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents-The Data from the Study among Healthcare Workers in an Infectious Diseases Center.
Skrzat-Klapaczyńska A; Kowalska JD; Paciorek M; Puła J; Bieńkowski C; Krogulec D; Stengiel J; Pawełczyk A; Perlejewski K; Osuch S; Radkowski M; Horban A
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560567
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
Diamantopoulos PT; Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Giannakopoulou N; Vardaka M; Mpouhla A; Mastrogianni E; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ther Adv Hematol; 2022; 13():20406207221090150. PubMed ID: 35646300
[TBL] [Abstract][Full Text] [Related]
33. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
34. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.
Lim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim SH; Kim CK; Kim T; Choo EJ; Moon JE; Yun J; Park SK
Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960125
[TBL] [Abstract][Full Text] [Related]
35. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
Vargas-Herrera N; Fernández-Navarro M; Cabezudo NE; Soto-Becerra P; Solís-Sánchez G; Escobar-Agreda S; Silva-Valencia J; Pampa-Espinoza L; Bado-Pérez R; Solari L; Araujo-Castillo RV
PLoS One; 2022; 17(10):e0268419. PubMed ID: 36251630
[TBL] [Abstract][Full Text] [Related]
37. Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers.
Niekrens V; Esse J; Held J; Knobloch CS; Steininger P; Kunz B; Seggewies C; Bogdan C
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632406
[TBL] [Abstract][Full Text] [Related]
38. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
39. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.
Grunau B; Golding L; Prusinkiewicz MA; Asamoah-Boaheng M; Armour R; Marquez AC; Jassem AN; Barakauskas V; O'Brien SF; Drews SJ; Haig S; Lavoie PM; Goldfarb DM
Microbiol Spectr; 2022 Apr; 10(2):e0270221. PubMed ID: 35254166
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 BNT162b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19 disease.
Kelsen SG; Braverman AS; Aksoy MO; Hayman JA; Patel PS; Rajput C; Zhao H; Fisher SG; Ruggieri MR; Gentile NT
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35019861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
